Does TAS2R38 signaling in sinonasal ciliated cells boost nitric oxide and mucociliary clearance?

The claim is biologically well supported at the epithelial level, with more cautious support for clinical susceptibility to persistent upper-airway disease. TAS2R38 function appears to link bacterial sensing to rapid sinonasal innate-defense responses.

Mechanistic and functional evidence

• In differentiated primary human sinonasal epithelial cultures, cilia-localized TAS2R38 responds to bacterial acyl-homoserine lactones and phenylthiocarbamide through PLCβ2/TRPM5-dependent calcium signaling, activating nitric-oxide synthase and generating nitric oxide (NO).
• NO has two complementary defense roles: it contributes directly to antibacterial activity in airway-surface liquid, including reported killing of Pseudomonas aeruginosa, and activates soluble guanylyl cyclase–cGMP–protein kinase G signaling. The latter increases ciliary beat frequency and mucociliary transport.
• This receptor-to-NO-to-clearance pathway is therefore a plausible, experimentally demonstrated mechanism by which sinonasal epithelium detects bacterial products and accelerates local defense.

Genetic implications and clinical relevance

• The functional PAV haplotype produces stronger agonist-induced calcium, NO, ciliary, transport, and bacterial-killing responses than the reduced-function AVI haplotype. Impairment is generally greatest in AVI/AVI cells, with PAV/AVI responses often intermediate.
• Clinical associations are less uniform. A 2022 systematic review including 22 studies and 3,845 participants found increased AVI/AVI frequency in four of six CRS studies, but larger cohorts often found no association. In surgical-predictor meta-analysis, AVI/AVI was associated with higher recurrence than PAV/PAV (OR 3.61, 95% CI 1.92–6.78), based on four studies with low-to-moderate certainty.

Bottom line

• TAS2R38 signaling robustly promotes NO-mediated antibacterial activity and mucociliary clearance in human sinonasal cells; AVI-containing reduced-function haplotypes can blunt these responses. They may mark higher risk or poorer outcomes in selected chronic rhinosinusitis populations, but do not establish an individual’s cause of persistent infection or support routine genotype-directed management.